CN1247201C - 核糖在预防肌肉痛性痉挛和疼痛中的用途 - Google Patents
核糖在预防肌肉痛性痉挛和疼痛中的用途 Download PDFInfo
- Publication number
- CN1247201C CN1247201C CNB008142769A CN00814276A CN1247201C CN 1247201 C CN1247201 C CN 1247201C CN B008142769 A CNB008142769 A CN B008142769A CN 00814276 A CN00814276 A CN 00814276A CN 1247201 C CN1247201 C CN 1247201C
- Authority
- CN
- China
- Prior art keywords
- ribose
- pain
- food
- purposes
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
- Finger-Pressure Massage (AREA)
Abstract
在运动前给予的核糖减轻或预防运动诱发的肌肉痛性痉挛和疼痛。在运动前服用核糖和在运动后立即服用核糖均可进一步减轻或预防运动诱发的肌肉痛性痉挛和疼痛。
Description
发明领域
本发明涉及用于预防肌肉痛性痉挛和疼痛的方法和组合物。本发明的方法和组合物特别适合于口服给药且用于预防或减轻运动诱发的肌肉痛性痉挛和疼痛。
发明背景
许多剧烈运动的人均在运动前后经历过不适的、令人痛苦的且可以导致出现被迫不活动期的肌肉痛性痉挛和疼痛的情况。足以导致这些令人痛苦的症状的运动程度随人与人的不同而改变。职业运动员或献身运动健康的人可以每天剧烈运动而不会诱发肌肉痛性痉挛和疼痛。大多数人不会得到这种水平的条件。对于平常人来说,运动局限在每周几次且这类人通常称作“周末勇士”。用于运动的时间受限阻止了他们获得使他们剧烈运动而不会出现肌肉痛性痉挛和疼痛的水平条件。肺功能降低的人在最低程度的运动时可能会出现这些症状。
肌肉痛性痉挛的原因尚不清楚。认为运动可导致一定程度的低氧。在已经提出的机理中,提出了由腺苷三磷酸分解或糖酵解的中间体、电解质失衡和乳酸形成而形成自由基的机理。肌肉疼痛的原因也不清楚。还将肌肉外伤导致肌红蛋白和电解质损失提出作为一个因愈合过程中的炎症反应导致的疼痛的原因。对预防或缓解肌肉痛性痉挛和疼痛的有效方式存在需求而并不关注机理。
标题为“用于在体内增加能量的组合物”(“COMPOSITION FORINCREASING ENERGY IN VIVO”)的且于1999年12月23日公开的同时待审申请WO 99/65476中公开了将核糖用于增加患有心血管疾病或外周血管疾病的健康人体内的能量。
发明概括
已经令人意外地观察到在运动前后服用单独的有效量的核糖或服用有效量的与电解质和其它碳水化合物一起联用的核糖可以减轻或缓解运动引起的肌肉痛性痉挛和疼痛。由此令人意外地发现核糖和含有它的组合物对希望运动和关注肌肉痛性痉挛和疼痛的危害、但并不必关注以WO 99/65476中公开的方式增加其能量水平的健康人而言具有价值。
因此,本发明的一个方面涉及一种用于预防哺乳动物(包括人)骨骼肌内因运动诱发的肌肉痛性痉挛和疼痛的方法,该方法包括在运动前足够的时间对所述哺乳动物给予有效量的核糖的步骤,使得核糖在运动过程中存在于所述哺乳动物的骨骼肌中。
在另一个方面中,本发明提供了核糖在制备用于在运动前给予哺乳动物(包括人)以抑制运动诱发的肌肉痛性痉挛和疼痛发生的膳食组合物中的用途。
发明详述
在肌肉收缩过程中,氧的需求可能超过氧的利用,即肌肉可能出现低氧情况。在运动的低氧的肌肉中,能量的产生将以需氧方式生产腺苷三磷酸(ATP)转变成以厌氧方式生产腺苷三磷酸(ATP)的形式进行。以厌氧方式由葡萄糖产生能量即糖酵解产生乳酸作为终产物。同时ATP分解成肌苷和次黄嘌呤,它进一步代谢产生自由基、即可导致细胞损害的极具反应性的分子。乳酸的存在、由自由基或某些其它机理导致的损害是否是肌肉痛性痉挛和疼痛的主要原因尚不清楚。
目前已经令人意外地发现核糖还可以缓解运动诱发的肌肉痛性痉挛和疼痛。不受理论的限制,认为在运动过程中存在核糖可缓解运动的即刻作用、即缓解痛性痉挛的作用,同时通过在运动后给予核糖重新补足肌肉中的核糖可缓解较后发生的疼痛。
本发明提供了核糖在制备用于在运动前给予哺乳动物以抑制运动诱发的肌肉痛性痉挛和疼痛发生的食品中的用途。
在本发明的一个实施方案中,所述的食品是饮料或饮料浓缩物。在本发明的另一个实施方案中,所述的食品是固体糖果。在本发明的另一个实施方案中,中所述的食品是膳食组合物。按照本发明,所述的食品是单位剂型。在本发明的一个实施方案中,所述的食品是可开口以便允许该内含物添加到食品或饮料中的囊剂的形式。
按照本发明,所述的核糖的用量为1-60g。在本发明的一个实施方案中,所述的核糖的用量为2-10g。
按照本发明,在运动前至少10分钟、但不超过4小时时给予所述的核糖。
在本发明中,所述的哺乳动物优选是人。
本发明提供了单独使用和与电解质和其它碳水化合物联用的用于诱发或缓解因运动诱发的肌肉痛性痉挛和疼痛的核糖。本发明还提供了用于产生最大有益作用的剂量和方案。
核糖是一种带有轻微甜味的简单的糖。用于预防痛性痉挛的必需量约为2-10克或约1/4至一茶匙干粉。可以将该粉末咽下、将其分散在谷类食品中或与诸如水、汁、茶或咖啡这样的任意常用液体混合。许多运动的人优选饮用诸如Gatorade、Thirst Quencher或Max这样的″可调换的″溶液。这些缓释能量的制品一般由下列成分中的某些或全部制成:碳水化合物,包括淀粉糖浆、蔗糖、果糖和麦芽糖糊精;蛋白质,包括酪蛋白和大豆蛋白;和脂类,包括玉米油、大豆油、红花油和canola油以及中链甘油三酯类。可以方便地将核糖加入到这些饮品中。还可以以足以预防肌肉痛性痉挛和疼痛的量将核糖加入到诸如Balance或Power Bar这样所谓的“热能棒”中。
我们已经发现在运动过程中确实是核糖的存在可有效预防痛性痉挛。因此,无论给予核糖的优选方式如何,重要的是在足够的时间前给予核糖以便将所述核糖在运动过程中转运至骨骼肌。如果将核糖溶于诸如水化汁这样的液体,那么15分钟足以将核糖导入循环系统并转运至肌肉。如果将核糖与固体食品共同给予,那么可以将吸收过程延缓至1小时。我们已经发现为了以最佳方式预防疼痛,有利的是可以在运动后立即再次服用核糖。因此,建议在运动前服用核糖且在运动后立即服用核糖以便预防痛性痉挛和疼痛。
下列实施例用来证明本发明的优选实施方案。在每个实施例中,将D-核糖作为优选的实施方案公开。然而,本领域技术人员已知易于将诸如木糖醇和核酮糖这样的某些戊糖在体内转化成D-核糖。因此,术语″核糖″用以包括D-核糖和这类核糖的前体。本领域技术人员应理解下面的实施例中公开的方法和剂量代表本发明者发现的用于充分实施本发明的方法和剂量且由此将它们看作构成实施本发明的优选方式。然而,本领域技术人员会理解可以根据本说明书公开的内容对所公开的实施方案进行许多改变且仍然可以获得类似或相似的结果而不会脱离本发明的构思和范围。将所有这类改变看作属于由所附权利要求定义的本发明的精神、范围和构思内。
实施例1 长距离赛跑者
43岁富有经验的男性马拉松赛跑者已经完成了15次马拉松。其训练方案由每周4-5次的8英里-10英里跑组成。在训练跑的过程中且尤其是在马拉松比赛前后,他已经经历了不同程度的肌肉痛性痉挛和疼痛。他在赛跑后还感觉到了疲劳。
他每天口服三次2-5克的D-核糖。正如所预计的,他感觉到能量提高且令人意外的是他没有经历肌肉痛性痉挛。在他的下一次马拉松中,″我令人惊讶地感到愉快而没有疲劳感且实际上是零痛性痉挛。我一直期待着去‘撞墙’,但在用核糖训练后那一时刻就始终没有到来。实际上我在整个26.2英里跑过程中感到能量供给极为充足。″
实施例2 因运动诱发的肌肉疼痛的缓解
41岁每周慢跑两英里一次或两次的女性经历了运动诱发的肌肉疼痛、从运动后的5-10小时开始并持续两天或三天。疼痛严重至足以使她无法舒适地训练。
她开始在跑前15-20分钟服用2-5克溶于约200ml水的D-核糖。在她进行20-30分钟训练和常规的伸展训练后,她再次服用溶于水的1克D-核糖。在第一次开始服用核糖时她即刻感觉到通常的肌肉疼痛得到缓解。而在服用核糖前,她感觉在5小时开始和最大在24小时的疼痛;在摄取核糖后的24小时时她仅感到轻度的僵硬,不足以防碍她训练。在她已服用核糖一周后,她开始经历了能量增加且疲劳感降低的过程。
该受试者在训练前后持续服用相同剂量的核糖且持续感觉到运动后仅轻度的强直和疼痛而能量增加且疲劳感降低。结果是她能够将每周1-2次的训练量增加到每周2-4次的训练量,其中每日定时活动中的能量和耐力均得到了有益的增加。
实施例3 肺气肿患者中肌肉痛性痉挛的缓解
患有肺气肿的中年女性患者在其手部、腿部和足部均经历过痛性痉挛和疼痛。这些症状甚至因轻度运动也会使之恶化。她开始在每天早晨服用2-4克剂量的D-核糖。她在当天根据其预定的活动水平调整所述剂量,从而为更多的活动天数时服用较高的剂量。她感觉到痛性痉挛直接和总体上缓解。在摄取核糖的4个月期间维持了这种缓解状态。
实施例4 网球选手肌肉疼痛的缓解
从事周末比赛的68岁网球选手在每次比赛后感觉到疲劳和肌痛。他发现因疼痛、强直和疲劳而难以连续打两天的网球,这种情况阻止了他集中精力进行第二天的比赛。这些症状的结果是他不能够竞争循环比赛及其需求。当周末比赛在极热和潮湿的天气下持续进行的过程中,他在第一天比赛后服用3克溶于桔子汁的D-核糖。第二天他就能够打出最高水平的比赛而不会感觉常见的疼痛和疲劳。
根据本说明书公开的内容可以制备并实施本文公开并要求保护的所有组合物和方法而不会有过度的实验过程。尽管已经根据优选的实施方案描述了本发明的组合物和方法,但是本领域技术人员显然可以对本文所述的组合物的和方法进行改变而不会脱离本发明的构思和范围。更具体地说,显然可以用化学上和生理学上相关的某些活性剂取代本文所述的活性剂而可以获得相同或相似的结果。认为对本领域技术人员而言属于显而易见的所有这类相似的取代和改均属于由所附权利要求所定义的本发明范围和构思内。
Claims (7)
1.核糖在制备用于在运动前给予哺乳动物以抑制运动诱发的肌肉痛性痉挛和疼痛发生的食品中的用途。
2.根据权利要求1的用途,其中所述的食品是饮料或饮料浓缩物。
3.根据权利要求1的用途,其中所述的食品是固体糖果。
4.根据权利要求1的用途,其中所述的食品是膳食组合物。
5.根据权利要求1-4中任意一项的用途,其中所述的食品是单位剂型。
6.根据权利要求5的用途,其中所述的食品是可开口以便允许该内含物添加到食品或饮料中的囊剂的形式。
7.根据权利要求1的用途,其中所述的哺乳动物是人。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/405,464 US6159943A (en) | 1999-09-24 | 1999-09-24 | Use of ribose to prevent cramping and soreness in muscles |
US09/405,464 | 1999-09-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1450904A CN1450904A (zh) | 2003-10-22 |
CN1247201C true CN1247201C (zh) | 2006-03-29 |
Family
ID=23603807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008142769A Expired - Lifetime CN1247201C (zh) | 1999-09-24 | 2000-09-22 | 核糖在预防肌肉痛性痉挛和疼痛中的用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US6159943A (zh) |
EP (1) | EP1235581B1 (zh) |
JP (3) | JP4945710B2 (zh) |
CN (1) | CN1247201C (zh) |
AT (1) | ATE322273T1 (zh) |
AU (1) | AU783796B2 (zh) |
BR (1) | BR0014235A (zh) |
CA (1) | CA2383284C (zh) |
DE (1) | DE60027197T2 (zh) |
ES (1) | ES2257319T3 (zh) |
GB (1) | GB2352175B (zh) |
MX (1) | MXPA02003150A (zh) |
WO (1) | WO2001020969A2 (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020119933A1 (en) * | 2000-07-28 | 2002-08-29 | Butler Terri L. | Compositions and methods for improving cardiovascular function |
US6511964B2 (en) | 1999-09-24 | 2003-01-28 | Bioenergy, Inc. | Method for treating acute mountain sickness |
US6159943A (en) * | 1999-09-24 | 2000-12-12 | Bioenergy, Inc. | Use of ribose to prevent cramping and soreness in muscles |
US6703370B1 (en) * | 1999-10-27 | 2004-03-09 | Bioenergy, Inc. | Use of ribose to treat fibromyalgia |
CA2325033C (en) * | 1999-10-27 | 2007-05-22 | Bioenergy Inc. | Use of ribose to treat fibromyalgia |
EP1282424A1 (en) | 2000-01-07 | 2003-02-12 | Bioenergy Inc. | compositions for enhancing the immune response |
WO2001052831A1 (en) | 2000-01-20 | 2001-07-26 | Bioenergy Inc. | Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans |
FR2822642B1 (fr) * | 2001-03-30 | 2005-03-04 | Roquette Freres | Denree alimentaire a liberation d'energie prolongee |
EP1247525A1 (en) * | 2001-04-02 | 2002-10-09 | Bioenergy Inc. | Use of a monosaccharide in the manufacture of a medicament against acute mountain sickness |
US7629329B2 (en) * | 2001-06-04 | 2009-12-08 | Tsi Health Sciences, Inc. | Method for increasing muscle mass and strength through administration of adenosine triphosphate |
US20030212006A1 (en) * | 2002-05-13 | 2003-11-13 | Seifert John G. | Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals |
US20050048136A1 (en) * | 2003-08-27 | 2005-03-03 | Choudhry Muhammad S. | Rehydrating beverage with Rhodiola crenulata and D-ribose that enhances blood oxygen and relieves post-exertional muscle cramping and soreness |
US20070105787A1 (en) * | 2004-01-14 | 2007-05-10 | St Cyr John A | Use of ribose in recovery from anaesthesia |
US20100099630A1 (en) * | 2004-04-29 | 2010-04-22 | Maccarter Dean J | Method for improving ventilatory efficiency |
ES2393786T3 (es) * | 2004-04-29 | 2012-12-28 | Ribocor, Inc. | Método para mejorar la eficacia ventilatoria |
US7968138B2 (en) * | 2004-07-23 | 2011-06-28 | Arnold Nerenberg | Food sweetener |
WO2006065881A2 (en) * | 2004-12-14 | 2006-06-22 | Bioenergy, Inc. | Use of ribose to alleviate rhabdomyolysis and the side effects of statin drugs |
US20070172542A1 (en) * | 2005-07-18 | 2007-07-26 | Next Proteins, Inc. | Stimulant-containing nutrition bar product and method of manufacture |
US7566463B2 (en) * | 2006-05-03 | 2009-07-28 | C. B. Fleet Company | Oral rehydration compositions |
JP5396387B2 (ja) * | 2007-01-23 | 2014-01-22 | バイオエナジー インコーポレイティド | 心臓不整脈を治療するためのd−リボースの用途 |
US20090061016A1 (en) * | 2007-09-05 | 2009-03-05 | Selzer Jonathan A | Seawater Based Dietary Supplement Product for Energy and Electrolyte Replacement |
CA2757442A1 (en) * | 2008-04-02 | 2009-10-08 | Bioenergy, Inc. | Use of ribose in first response to acute myocardial infarction |
CA2734769A1 (en) * | 2008-08-20 | 2010-02-25 | Bioenergy, Inc. | Use of d-ribose for fatigued subjects |
WO2012027277A2 (en) * | 2010-08-21 | 2012-03-01 | Hydropep, Llc | Compositions for reducing the deleterious effects of stress and aging |
EP3411041A1 (en) | 2016-02-01 | 2018-12-12 | RiboCor, Inc. | Use of ribose for treatment of subjects having congestive heart failure |
US20190313682A1 (en) * | 2018-04-12 | 2019-10-17 | Metabolic Recovery Systems, LLC | Compositions and methods for supplementing the diet |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH570122A5 (zh) * | 1970-12-23 | 1975-12-15 | Givaudan & Cie Sa | |
JPS5921376A (ja) * | 1982-07-26 | 1984-02-03 | Akiji Kotani | 魚肉ねり製品発色剤、および魚肉ねり製品の発色方法 |
US4605644A (en) * | 1985-02-07 | 1986-08-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia employing ribose and adenine |
US4719201A (en) * | 1985-02-07 | 1988-01-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia |
US4824660A (en) * | 1985-06-06 | 1989-04-25 | Paul S. Angello | Method of determining the viability of tissue in an organism |
JPS6232860A (ja) * | 1985-08-06 | 1987-02-12 | Riichiro Yamazaki | 健康食品 |
US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
US4828845A (en) * | 1986-12-16 | 1989-05-09 | Warner-Lambert Company | Xylitol coated comestible and method of preparation |
US4871718A (en) * | 1987-12-29 | 1989-10-03 | Raymond A. Roncari | Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair |
US4968719A (en) * | 1989-04-03 | 1990-11-06 | Sigma Tau, Industrie Farmaceutiche Riunite Spa | Method for treating vascular disease |
US5114723A (en) * | 1990-02-27 | 1992-05-19 | University Of Texas System Board Of Regents | Beverage compositions for human consumption |
CA2048003A1 (en) * | 1990-08-21 | 1992-02-22 | Serge Burner | Tricyclic pyridone derivatives |
GB9101244D0 (en) * | 1991-01-19 | 1991-02-27 | Wellcome Found | Amide derivatives and their therapeutic use |
IT1247125B (it) * | 1991-03-01 | 1994-12-12 | Depha Team Srl | Composizioni dietetiche o farmaceutiche per il ripristino del contenuto cellulare degli adenin nucleotidi nel muscolo scheletrico e cardiaco. |
US5292538A (en) * | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
DE4228215A1 (de) * | 1992-08-25 | 1994-03-03 | Pliml Wolfgang | Verwendung von Ribose zur Herstellung eines Arzneimittels zur Behandlung von Leistungsschwächen des Körpers, insbesondere von Organinsuffizienzen |
US5536751A (en) * | 1994-05-09 | 1996-07-16 | The United States Of America As Represented By The Secretary Of The Army | Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof |
EP0729758A3 (en) * | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases |
US5707971A (en) * | 1995-06-07 | 1998-01-13 | Life Resuscitation Technologies, Inc. | Modulation of glycolytic ATP production |
GB9715340D0 (en) * | 1997-07-22 | 1997-09-24 | Cerestar Holding Bv | Beverages for enhanced physical performance |
JP4295840B2 (ja) * | 1997-12-09 | 2009-07-15 | 株式会社林原生物化学研究所 | 血行改善剤 |
US6159942A (en) * | 1998-06-19 | 2000-12-12 | Bioenergy, Inc. | Compositions for increasing energy in vivo |
US6159943A (en) * | 1999-09-24 | 2000-12-12 | Bioenergy, Inc. | Use of ribose to prevent cramping and soreness in muscles |
-
1999
- 1999-09-24 US US09/405,464 patent/US6159943A/en not_active Expired - Lifetime
-
2000
- 2000-09-21 GB GB0023103A patent/GB2352175B/en not_active Expired - Lifetime
- 2000-09-22 BR BR0014235-2A patent/BR0014235A/pt not_active Application Discontinuation
- 2000-09-22 ES ES00963748T patent/ES2257319T3/es not_active Expired - Lifetime
- 2000-09-22 WO PCT/US2000/026140 patent/WO2001020969A2/en active IP Right Grant
- 2000-09-22 AT AT00963748T patent/ATE322273T1/de not_active IP Right Cessation
- 2000-09-22 AU AU38842/01A patent/AU783796B2/en not_active Expired
- 2000-09-22 CN CNB008142769A patent/CN1247201C/zh not_active Expired - Lifetime
- 2000-09-22 JP JP2001524411A patent/JP4945710B2/ja not_active Expired - Lifetime
- 2000-09-22 MX MXPA02003150A patent/MXPA02003150A/es unknown
- 2000-09-22 CA CA2383284A patent/CA2383284C/en not_active Expired - Lifetime
- 2000-09-22 EP EP00963748A patent/EP1235581B1/en not_active Expired - Lifetime
- 2000-09-22 DE DE60027197T patent/DE60027197T2/de not_active Expired - Lifetime
-
2010
- 2010-12-03 JP JP2010270608A patent/JP6096401B2/ja not_active Expired - Lifetime
-
2014
- 2014-12-05 JP JP2014247292A patent/JP2015052018A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE60027197T2 (de) | 2006-08-24 |
AU3884201A (en) | 2001-04-24 |
ATE322273T1 (de) | 2006-04-15 |
DE60027197D1 (de) | 2006-05-18 |
JP2003516315A (ja) | 2003-05-13 |
JP2015052018A (ja) | 2015-03-19 |
EP1235581B1 (en) | 2006-04-05 |
US6159943A (en) | 2000-12-12 |
MXPA02003150A (es) | 2003-08-20 |
AU783796B2 (en) | 2005-12-08 |
BR0014235A (pt) | 2002-12-31 |
WO2001020969A3 (en) | 2002-07-11 |
CN1450904A (zh) | 2003-10-22 |
GB2352175B (en) | 2001-07-18 |
EP1235581A2 (en) | 2002-09-04 |
CA2383284A1 (en) | 2001-03-29 |
GB2352175A (en) | 2001-01-24 |
JP2011093910A (ja) | 2011-05-12 |
ES2257319T3 (es) | 2006-08-01 |
GB0023103D0 (en) | 2000-11-01 |
WO2001020969A2 (en) | 2001-03-29 |
JP6096401B2 (ja) | 2017-03-15 |
CA2383284C (en) | 2011-03-15 |
JP4945710B2 (ja) | 2012-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1247201C (zh) | 核糖在预防肌肉痛性痉挛和疼痛中的用途 | |
US4981687A (en) | Compositions and methods for achieving improved physiological response to exercise | |
AU2004289359B2 (en) | Carbohydrate and electrolyte replacement composition | |
JPH09504945A (ja) | 新規飲料 | |
Shirreffs | The optimal sports drink | |
CN105661234A (zh) | 一种迅速恢复体能的饮料及其制备方法 | |
US20060172016A1 (en) | Muscle cramp reliever | |
JP2009545298A (ja) | 再生効果を有する食品中のイソマルツロースの使用方法 | |
US5238684A (en) | Compositions and methods for achieving improved physiological response to exercise | |
CN107485619A (zh) | 一种b族维生素复合物及其制备方法 | |
KR100364000B1 (ko) | 스포츠 음료 조성물 및 이의 제조 방법 | |
JPH06125739A (ja) | 運動維持飲用組成物 | |
RU2529155C1 (ru) | Шоколад для спортивного питания "шокоспорт" | |
US20050048136A1 (en) | Rehydrating beverage with Rhodiola crenulata and D-ribose that enhances blood oxygen and relieves post-exertional muscle cramping and soreness | |
Maughan | Sports nutrition: an overview | |
CN106173672A (zh) | 一种运动型饮料及其制备方法 | |
JPH01269456A (ja) | スポーツ用食品 | |
EP2044853B1 (en) | Nutriment for use for accelerated physiological performance enhancement | |
Ludwig et al. | Causes of obesity | |
Luotonen | Effects of carbohydrate content on body composition during weight loss in female fitness competitors | |
Love | The Effects Of Low-Carbohydrate Fad Diets On The Performance Of Competitive Tennis Play | |
Paker | Nutrition in Sports | |
David Brady et al. | D-Ribose | |
Campbell | Nutrient Timing | |
Stout | Diet Facts, Fallacies and Strategies for Building Muscle and Burning Fat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BIOLOGICAL ENERGY LIFE SCIENCE CO. Free format text: FORMER OWNER: BIOENERGY INC. Effective date: 20120727 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120727 Address after: Minnesota, USA Patentee after: Biological Energy Life Science Co. Address before: American Minnesota Patentee before: Bioenergy, Inc. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060329 |